Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + cisplatin induction, cisplatin CCRT, gemcitabine adjuvant in locally advanced nasopharyngeal carcinoma
ChiCTR-OIC-17011464Phase 2Not yet recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and gemcitabine in nasopharyngeal carcinoma (NPC), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Distant failure-free survival rate. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
docetaxelcisplatingemcitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-OIC-17011464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011464.